Program in Cardiovascular and Metabolic Disorders, Duke-NUS Graduate Medical School Singapore, Singapore.
Address correspondence to: Shirish Shenolikar, Program in Cardiovascular and Metabolic Disorders, Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore 169857, Singapore. Phone: 65.6516.2588; Fax: 65.6220.8161; E-mail: shirish.shenolikar@duke-NUS.edu.sg.
First published February 24, 2014 - More info
See the related article beginning on page 1406.
BRAF mutations in aggressive melanomas result in kinase activation. BRAF inhibitors reduce BRAFV600E tumors, but rapid resistance follows. In this issue of the JCI, Ma and colleagues report that vemurafenib activates ER stress and autophagy in BRAFV600E melanoma cells, through sequestration of the ER chaperone GRP78 by the mutant BRAF and subsequent PERK activation. In preclinical studies, treating vemurafenib-resistant melanoma with a combination of vemurafenib and an autophagy inhibitor reduced tumor load. Further work is needed to establish clinical relevance of this resistance mechanism and demonstrate efficacy of autophagy and kinase inhibitor combinations in melanoma treatment.
Molecular analyses of human tumors have highlighted the numerous mutations in protein kinase genes that contribute to the development of cancers. For example, the gene encoding BRAF kinase is mutated in more than 60% of melanomas, the most aggressive human skin cancer. Indeed, a mutation that results in a single amino acid substitution, V600E, accounts for 90% of identified BRAF mutations. It is worth noting that this “oncogenic” BRAF (BRAFV600E) is present in many melanocytic nevi, which are benign neoplasias that can persist for decades without transitioning to malignancy (1). The fact that BRAFV600E-containing melanocytic nevi are not intrinsically aggressive hints that additional steps — such as acquisition of further mutations, metabolic reprogramming (2), or alterations in other cellular processes — are required for conversion of the proliferative melanocytes into full-fledged malignant melanomas. This raises the exciting possibility that understanding some of the internal brakes on malignancy will yield novel treatments for melanoma that fails to respond to most current anticancer therapies.
Cancer-promoting mutations frequently result in constitutive activation of the mutant kinase, which has prompted pharmaceutical companies to develop kinase inhibitors to slow or reverse the oncogenic process (3). However, the networks of signaling pathways that control cell growth in normal and cancer cells means that most kinase inhibitors are cytostatic, causing cell cycle arrest rather than cell death. Some kinase inhibitors, however, show spectacular results in eradicating tumor cells. For example, the BCR-ABL tyrosine kinase inhibitor imatinib elicits greater than 80% response in the chronic phase of chronic myeloid leukemia (CML). Similarly, the BRAF inhibitor vemurafenib shows dramatic responses in melanoma patients harboring the BRAFV600E mutation (4). For both imatinib and vemurafenib, drug resistance emerges rapidly in nearly all patients. Understanding how these drugs instigate cell death and the molecular basis underlying resistance should facilitate future development of improved anticancer therapies.
The combination of an unfavorable microenvironment, a poor nutrient supply, and the energy demands associated with increased protein synthesis in rapidly proliferating cancer cells create ER stress. In melanoma cells, ER stress is reflected by elevated expression of the ER luminal marker glucose-regulated protein 78 (GRP78; also known as BIP) (Figure 1 and ref. 5). Additionally, there is growing awareness that many anticancer therapies induce ER stress, which plays a key role in triggering apoptosis, or programmed cell death, in tumor cells. For instance, vemurafenib has been shown to activate ER stress signaling pathways in melanoma cells, specifically those triggered by the ER membrane–localized sensors PERK, ATF6, and IRE1. In BRAFV600E melanoma cells, knockdown of ATF4, an ER stress–induced transcription factor acting in the PERK pathway, markedly reduced vemurafenib-associated cell death. Conversely, vemurafenib combined with either thapsigargin or tunicamycin, both of which are known inducers of ER stress, enhanced apoptosis in vemurafenib-resistant or -insensitive melanoma cells (6). These results suggest that pharmacological enhancers of ER stress, particularly those that stimulate the PERK pathway, may be useful adjuncts to vemurafenib treatment and may overcome the rapidly developing drug resistance seen in melanoma patients.
The BRAF inhibitor vemurafenib activates ER stress. Vemurafenib promotes the association of BRAFV600E with GRP78 in the ER in drug-sensitive (A) and drug-resistant (B) melanoma cells. This association displaces GRP78 from PERK, resulting in robust autophosphorylation and kinase activation. The ensuing PERK-mediated phosphorylation of eIF2α initiates a transcriptional and translational cascade that is mediated by expression of the transcription factors ATF4 and CHOP. These nuclear factors either act alone or together to promote the expression of numerous proapoptotic — and, paradoxically, also autophagic (11) — genes. Vemurafenib treatment also results in IRE1 activation and subsequent splicing of the mRNA encoding X-box binding protein 1 (XBP1), a transcription factor that regulates ER-associated protein degradation in response to ER stress. In drug-sensitive melanomas (A), apoptosis prevails, while in drug-resistant tumor cells (B), autophagy may override apoptosis. The factors that shift the balance from apoptosis to autophagy in response to vemurafenib treatment remain unknown, but could include the expression of cellular IAPs or expression of other antiapoptotic genes that contribute to tumor survival in the presence of the BRAF inhibitor. The present findings of Ma et al. (8) suggest that autophagy inhibitors combined with vemurafenib may be an effective therapy for melanoma that would eliminate both drug-sensitive and drug-resistant tumor cells.
The transient activation of the PERK, ATF6, and IRE1 ER stress–activated pathways constitutes a normal homeostatic mechanism present in all mammalian cells to cope with unfavorable environmental conditions. In contrast, persistent signaling via the PERK (and IRE1) pathway promotes apoptosis, eliminating damaged or dysfunctional cells and preserving overall tissue function. The PERK pathway also stimulates autophagy to salvage components of the damaged cells that can be used to sustain the remaining cells (Figure 1 and ref. 5). In a cancer setting, autophagy frequently overrides or overcomes ER stress–induced cell death; therefore, therapy-induced ER stress, which is frequently accompanied by enhanced autophagy, may contribute to the development of drug resistance. In CML cells, attenuating autophagy in combination with imatinib therapy enhances cell death and even eliminates CML stem cells, which are often difficult to eradicate with imatinib alone (7). In this issue of the JCI, Ma et al. reveal that autophagy is also elevated in melanoma tumor samples from patients treated with the BRAF inhibitors vemurafenib and dabrafenib (8). Autophagy biomarkers were also increased in samples taken after the emergence of drug resistance compared with samples taken prior to treatment. Furthermore, BRAF inhibitor–induced autophagy was preceded by ER stress in both drug-sensitive and -resistant BRAFV600E melanoma cell lines. Importantly, autophagy inhibition enhanced kinase inhibitor–induced cell death both in culture and in a mouse xenograft melanoma model. Together, these findings raise new hopes that a similar drug combination strategy may limit drug resistance and improve the efficacy of current treatment regimens for malignant melanoma.
The work by Ma and colleagues (8) also provides mechanistic insight into the actions of BRAF inhibitors, suggesting that they act upstream of PERK and promote PERK autophosphorylation, which is canonically activated in response to misfolded proteins in the ER. Misfolded proteins displace GRP78, which suppresses PERK kinase activity by binding its ER luminal domain. GRP78 displacement promotes PERK dimerization and autophosphorylation, increasing PERK activity, as evidenced by the enhanced phosphorylation of the eukaryotic initiation factor eIF2α and the subsequent attenuation of mRNA translation. Remarkably, Ma and colleagues found that BRAF inhibitors enhanced GRP78 binding to BRAFV600E within the ER lumen, and this interaction correlated with a reduction in GRP78 binding to PERK (8). These data suggest that in the presence of BRAF inhibitors, BRAFV600E outcompetes PERK for GRP78 binding, thereby explaining the activation of PERK by these drugs. The interaction between GRP78 and BRAFV600E is somewhat surprising, because GRP78 is a well-recognized ER luminal chaperone and possesses a C-terminal KDEL ER retention sequence. However, some studies have suggested that GRP78 can be translocated to the cytosol and plasma membrane in response to ER stress (9). In contrast, BRAF is primarily cytoplasmic, although one report suggests that a small fraction of BRAF in thyroid cancer cells may be associated with mitochondria. To date, the ER localization of BRAF — either WT or mutant forms of the protein — has not been reported. Substantially less BRAFV600E bound to GRP78 in the absence of BRAF inhibitors in the cytoplasm.
An interpretation of the work of Ma et al. (8) might be that BRAF inhibitors promote the translocation of BRAFV600E to ER, a major site of GRP78 in cells, thereby enhancing the BRAF/GRP78 interaction. A puzzling aspect is the apparent finding that PERK was preferentially or selectively activated after GRP78 binding to BRAF. The ER luminal domains of the three ER stress sensors, PERK, ATF6, and IRE1, are highly homologous, and all three proteins bind GRP78; therefore, it would be expected that the sequestration of GRP78 by BRAFV600E might activate all three ER stress–signaling pathways. On the other hand, earlier studies have shown that GRP78, which is induced by ATF6, is decreased in melanoma cells after vemurafenib exposure (6). At this stage, not only is it unclear how BRAF inhibitors promote BRAF entry into the ER, but it also remains to be determined how and why the sequestration of GRP78 by BRAF preferentially activates PERK. Another complicating factor is the recent finding that vemurafenib displaces BRAFV600E from the HSP90/CDC37 chaperone/cochaperone complex (10). The displaced BRAFV600E is unstable and is degraded by the proteasome, which suggests that this kinase inhibitor achieves some of its therapeutic effect by reducing cellular BRAFV600E levels. Whereas these data indicate that vemurafenib decreases both GRP78 and BRAFV600E levels in melanoma cells, Ma and colleagues demonstrated an enhanced association of GRP78 and BRAFV600E in the presence of this BRAF inhibitor (8). Thus, more work is clearly needed to fully understand these differing effects of the BRAF inhibitor and their impact on ER stress in vemurafenib-treated cells.
In summary, recent studies highlight the ability of anticancer therapies to activate ER stress, which may be critical for the induction of apoptosis in tumor cells; however, therapy-induced ER stress, specifically that associated with PERK activation, also promotes cancer cell survival via activation of autophagy (11). Other studies suggest that the PERK pathway also enhances the expression of inhibitors of apoptosis (IAPs), which are frequently elevated in melanoma cells and may also contribute to cancer cell survival or drug resistance. An emerging strategy for a more effective anticancer therapy is to combine kinase inhibitors with autophagy inhibitors to achieve the best clinical outcomes for CML and melanoma. The inclusion of IAP-inhibiting compounds to enhance apoptosis may also help reduce the rapid resistance to the frontline drugs. It will be exciting to see just how this new strategy plays out in the coming years and whether it offers new hope for the eradication of the aforementioned cancers.
The author’s research is supported by grants from National Medical Research Council and Biomedical Research Council of Singapore as well as by a Duke/Duke-NUS Collaborative Research Grant. Additional funding was provided through a GlaxoSmithKline Academic Center of Excellence (ACE) Award.
Conflict of interest: The author’s research is supported in part by an Academic Center of Excellence (ACE) Award from GlaxoSmithKline Inc.
Citation for this article:J Clin Invest. 2014;124(3):973–976. doi:10.1172/JCI74609.
See the related article beginning on page 1406.